Search hospitals > Massachusetts > Boston
Dana Farber Cancer Institute
Claim this profileBoston, Massachusetts 02215
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Solid Tumors
Conducts research for Lung Cancer
Conducts research for Pancreatic Cancer
3428 reported clinical trials
268 medical researchers
Summary
Dana Farber Cancer Institute is a medical facility located in Boston, Massachusetts. This center is recognized for care of Cancer, Breast Cancer, Solid Tumors, Lung Cancer, Pancreatic Cancer and other specialties. Dana Farber Cancer Institute is involved with conducting 3,428 clinical trials across 1,488 conditions. There are 268 research doctors associated with this hospital, such as Susan Chi, MD, Geoffrey I. Shapiro, Haeseong Park, MD, and Ryan Sullivan, MD.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
HER2 negative
2Breast Cancer
Global LeaderStage IV
Stage III
HER2 negative
Top PIs
Susan Chi, MDDana-Farber Cancer Institute5 years of reported clinical research
Expert in Brain Tumor
Expert in Diffuse Intrinsic Pontine Glioma
29 reported clinical trials
62 drugs studied
Geoffrey I. ShapiroDana-Farber Cancer Institute8 years of reported clinical research
Expert in Cancer
Expert in Pancreatic Cancer
27 reported clinical trials
57 drugs studied
Haeseong Park, MDWashington University School of Medicine7 years of reported clinical research
Studies Solid Tumors
Studies Pancreatic Cancer
27 reported clinical trials
55 drugs studied
Ryan Sullivan, MDMassachusetts General Hospital4 years of reported clinical research
Expert in Melanoma
Expert in Solid Tumors
22 reported clinical trials
35 drugs studied
Clinical Trials running at Dana Farber Cancer Institute
Breast Cancer
Lung Cancer
Ovarian Cancer
Multiple Myeloma
Prostate Cancer
Cancer
Chronic Lymphocytic Leukemia
Melanoma
Brain Tumor
Testicular cancer
Avelumab + Palbociclib/Hydroxychloroquine
for Breast Cancer
This clinical trial will assess the safety and early efficacy of Hydroxychloroquine or Avelumab, with or without Palbociclib, in early-stage ER+ breast cancer patients who are found to harbor disseminated tumor cells (DTCs) in the bone marrow after definitive surgery and standard adjuvant therapy.
Recruiting3 awards Phase 212 criteria
CDK4/6 Inhibitors
for Metastatic Breast Cancer
The purpose of this study is to generate evidence on an alternative dosing strategy for CDK4/6 inhibitors to help more patients with Metastatic Breast Cancer (MBC) (age ≥ 65 years) tolerate side effects and stay on treatment longer, to derive the most clinical benefit from these drugs. The primary objective of the CDK Study is to compare time to treatment discontinuation (TTD) on the approved dosing for palbociclib (125 mg orally daily on days 1-21 of 28-day cycle) or ribociclib (600 mg orally daily on days 1-21 of 28-day cycle) vs. TTD using titrated dosing approach with the same schedule but starting at a lower dose of palbociclib (100 mg or 75 mg) or ribociclib (400 mg or 200 mg) and escalating the dose if well-tolerated in combination with provider/patient choice endocrine therapy (aromatase inhibitor (AI) or fulvestrant) in patients age 65 or older with HR+/HER2- MBC. The secondary and exploratory objectives will generate evidence needed to personalize treatment decisions by comparing patient-centric secondary outcomes and evaluating baseline factors. Together with their treating physician, participants will choose the CDK4/6 inhibitor (palbociclib or ribociclib) and which endocrine therapy (aromatase inhibitor or fulvestrant) of their choice but will be randomized to either Arm 1 (indicated dosing) or Arm 2 (titrated dosing). Note: Telehealth visits are allowed at any time per institutional guidelines. In addition, the study allows for remote consenting per institutional guidelines.
Recruiting2 awards Phase 33 criteria
Giredestrant vs. Fulvestrant
for Advanced Breast Cancer
This trial is testing two drug combinations to treat a specific type of advanced breast cancer that no longer responds to standard hormone treatments. The goal is to see which combination works better by stopping the cancer cells from growing.
Recruiting2 awards Phase 38 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Dana Farber Cancer Institute?
Dana Farber Cancer Institute is a medical facility located in Boston, Massachusetts. This center is recognized for care of Cancer, Breast Cancer, Solid Tumors, Lung Cancer, Pancreatic Cancer and other specialties. Dana Farber Cancer Institute is involved with conducting 3,428 clinical trials across 1,488 conditions. There are 268 research doctors associated with this hospital, such as Susan Chi, MD, Geoffrey I. Shapiro, Haeseong Park, MD, and Ryan Sullivan, MD.
Where is Dana Farber Cancer Institute located?
The Dana Farber Cancer Institute is situated at 450 Brookline Ave, Boston, MA 02215, within the Longwood Medical Area. For access from the north, utilize I-93, the Tobin Bridge (Route 1), and Route 28, directing towards Storrow Drive, then proceed for 1.5 miles. Follow the exit for Kenmore Square/Fenway, Route 1S, stay in the far left lane, and continue onto Boylston Street (outbound), then bear slight left onto Brookline Avenue, and turn left onto Jimmy Fund Way to find the parking garage entrance on the right.
Who should I call to ask about financial aid or insurance network?
**Dana Farber Cancer Institute Contact Information:**
- **Patient Billing Solutions Team:** For general financial inquiries and assistance with the Patient Financial Assistance program, call 617-632-3795.
- **Shapiro Center for Patients and Families:** For insurance and financial information questions, contact 617-632-3750.
- **International Office:** Specialized support for international patients is available.
- **Language Assistance:** Spanish-speaking patients can call 617-632-3673. For all other languages, please call 617-632-6366.
**Address:** 450 Brookline Ave., Boston, MA 02215-5450.
What insurance does Dana Farber Cancer Institute accept?
The Dana Farber Cancer Institute accepts a wide range of insurance plans, such as Aetna, Allways Health Partners, AmeriHealth, Anthem, Cigna, Humana, Oscar, and UnitedHealthcare. It is now an in-network provider for the Boston Medical Center HealthNet Plan (BMCHP), catering to Massachusetts residents, including MassHealth members from marginalized communities, individuals with disabilities, and seniors. The hospital offers specialized services for international patients and financial counseling for uninsured or low-income individuals to explore coverage options.
What awards or recognition has Dana Farber Cancer Institute received?
The Dana-Farber Cancer Institute in Boston, Massachusetts, is renowned for its exceptional research and care in the field of cancer. It has been recognized as one of the most noteworthy companies and non-profits led by women in Massachusetts. Furthermore, 24 of its researchers have been acknowledged as Highly Cited Researchers, underscoring their significant global impact on cancer research.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.